Search Results
Aug 06, 2026, 17:00 ET Canada Nickel Reports Additional Exploration Drilling Results and Highest Grade Intervals to Date at Reid Nickel Sulphide Project
Co %Pd g/tPt g/t
More news about: Canada Nickel Company Inc.
Aug 06, 2026, 07:30 ET Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
double-blind, placebo-controlled, multiple ascending dose (MAD) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of repeated intrathecal injections of RAG-17 in patients with SOD1 mutations. The participating sites include
More news about: Ractigen Therapeutics
Aug 06, 2026, 07:00 ET 再鼎醫藥公佈2026年第二季度財務業績及近期公司進展
（LRRC15 ADC）預計於2027年上半年提供評估ZL-6201用於肉瘤和特定腫瘤患者的全球1a/b期研究劑量遞增部分的主要結果。ZL-1222（PD-1/IL-12）預計於2027年在美國提交一項新藥臨床試驗申請，並啟動一項全球1期研究。ZL-1311（MUC17/CD3）
More news about: 再鼎醫藥
Aug 06, 2026, 05:14 ET Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance
disease has developed resistance to prior immune checkpoint inhibitor therapy—settings in which effective treatment options remain limited.PD-1 and PD-L1 immune checkpoint inhibitors have transformed cancer care over the past decade. However, a substantial proportion of patients either do not respond
More news about: Senhwa Biosciences, Inc.
Aug 06, 2026, 00:51 ET Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
small nucleic acids. It has achieved a series of breakthroughs that are benefiting patients worldwide. As the world's first monoclonal antibody targeting PD-1 approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), HANSIZHUANG has been approved for marketing in over 40 countries
More news about: Fosun
Aug 05, 2026, 20:00 ET Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
IBI363/TAK-928 (PD-1/IL-2α-biased bispecific fusion protein)IBI363 is a first-in-class PD-1/IL-2α-biased bispecific antibody fusion protein being co-developed by Innovent Biologics and Takeda (Takeda R&D code: TAK-928). It functions by both blocking the PD-1/PD-L1 pathway and
More news about: Innovent Biologics
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
DeLLphi-303, a Phase 1b study of IMDELLTRA in combination with a programmed cell death protein ligand-1 (PD-L1) inhibitor, carboplatin and etoposide or separately in combination with a PD-L1 inhibitor alone, is ongoing in patients with first-line ES-SCLC.DeLLphi-305, a Phase 3 study of IMDELLTRA
More news about: Amgen
Aug 04, 2026, 10:00 ET Q2BI Expands Asia-Pacific Footprint with New Offices in Taipei, Kuala Lumpur, and Melbourne
in 2009, Q2BI has grown into an organization of more than 300 professionals across clinical data management, biostatistics, statistical programming, PK/PD, medical writing, medical monitoring and review, safety surveillance, regulatory support, data science, and software engineering. This multidisciplinary
More news about: Q-Square Business Intelligence (Q2BI)
Aug 04, 2026, 08:21 ET FDA Grants Fast Track Designation to Xellsmart Off-The-Shelf Cell Therapy for Parkinson's Disease
Parkinson's Disease and XS411Parkinson's disease (PD) ranks as the second-leading neurodegenerative disease globally. Epidemiological statistics indicate more than 10 million patients worldwide, including approximately 4 million cases across China. PD is characterized by progressive degeneration and
More news about: XellSmart Biopharmaceutical Co., Ltd.
Aug 04, 2026, 06:00 ET IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
investigator's choice of therapy (ICT) arm reflective of real-world clinical practice that included ipilimumab plus nivolumab (anti-CTLA-4/PD-1) or pembrolizumab (anti-PD-1). The primary endpoint is median progression-free survival (PFS) as assessed by blinded independent central review (BICR). Secondary
More news about: IDEAYA Biosciences, Inc.
Aug 03, 2026, 16:05 ET Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
presentation at the 2026 ASCO Annual Meeting showing improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patients.FDA granted Breakthrough Therapy designation (BTD) for zanidatamab in adults with previously treated locally
More news about: Jazz Pharmaceuticals plc
Aug 03, 2026, 16:05 ET Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
presentation at the 2026 ASCO Annual Meeting showing improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patients.FDA granted Breakthrough Therapy designation (BTD) for zanidatamab in adults with previously treated locally
More news about: Jazz Pharmaceuticals plc
Aug 03, 2026, 07:45 ET Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
granted Breakthrough Therapy designation, in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 expression ≥ 50%, as determined by FDA approved tests.
More news about: Eli Lilly and Company
Aug 03, 2026, 07:30 ET Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology
Peyronie's DiseasePeyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.1 It is estimated that PD can affect as many as 1 in 10 men in the U.S.,2* but
More news about: Keenova Therapeutics
Aug 03, 2026, 07:00 ET Compugen Reports Second Quarter 2026 Results
clinical rationale for evaluating COM701 in this population, including the differentiated biology of the PVRIG pathway versus other checkpoints such as PD-1 and TIGIT, its high expression in ovarian cancer, and the durable responses previously observed with COM701 as mono- and combination therapy in heavily
More news about: Compugen Ltd.
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
for its drug RP1 (vusolimogene oderparepvec) in combination with Bristol Myers Squibb's PD-1 inhibitor Opdivo for adults with unresectable advanced cutaneous melanoma who experience disease progression after a PD-1-blocking antibody-based therapy. Specifically, the FDA's briefing documents said that
More news about: Pomerantz LLP
Jul 30, 2026, 09:06 ET HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates
program supports AI drug-discovery teams in translating AI-generated targets, molecules and mechanism hypotheses into in vivo pharmacology, mechanism, PK/PD, biomarker and pre-IND translational evidence in autoimmune and allergy disease models. HKEY-AI2Vivo™ 1.0 at a GlanceWhat it
More news about: HKeyBio
Jul 30, 2026, 08:30 ET Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ANPD001) to Treat Parkinson's Disease
beginning with neurodegenerative diseases of high unmet need including PD.Its lead product candidate is sasineprocel (ANPD001), the most advanced autologous investigational cell therapy in the United States for treating PD. About Sasineprocel (ANPD001)Sasineprocel is a single-dose,
More news about: Aspen Neuroscience, Inc.
Jul 30, 2026, 08:30 ET Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
carcinoma (HNSCC). If approved, it would provide a new treatment for patients whose disease has progressed following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions and
More news about: Johnson & Johnson
Jul 30, 2026, 05:09 ET NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
metastatic NSCLC who have PD-L1 tumor proportion score (TPS)≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative; and 2) sac‑TMT as first‑line treatment for patients with recurrent or metastatic TNBC who have a PD‑L1 CPS <10 or have recurred after prior PD‑1/PD‑L1 inhibitor therapy in
More news about: Kelun-Biotech
Jul 30, 2026, 05:06 ET 邁向晚期TNBC一線治療！蘆康沙妥珠單抗(sac-TMT)第六項NDA獲受理
ADC藥物。蘆康沙妥珠單抗(sac-TMT)的兩項新增適應症上市申請已獲NMPA受理，分別用於1)聯合帕博利珠單抗(可瑞達®[1])一線治療PD-L1腫瘤比例分數(TPS)≥1%的EGFR基因突變陰性和間變性淋巴瘤激酶(ALK)陰性的局部晚期或轉移性NSCLC; 2) PD-L1 CPS<10或早期階段接受過PD-1/PD-L1抑制劑的復發或轉移性TNBC的一線治療，兩項申請均被納入優先審評審批程序。目前，科倫博泰已在中國開展9項註冊性臨床研究。默沙東已啟動17項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。關於科倫博泰四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，
More news about: 科倫博泰
Jul 29, 2026, 08:30 ET Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
for the treatment of adult patients with unresectable malignant pleural mesothelioma whose disease has progressed on or after prior treatment with anti-PD-1 antibody therapy, with or without anti-CTLA-4 antibody therapy, and platinum-based chemotherapy. According to the FDA's relevant policy, Fast
More news about: Insilico Medicine
Jul 28, 2026, 09:04 ET Parkinson's Foundation Awards Grants in 41 States for Parkinson's Community Programs
grants for Parkinson's disease (PD) programs across the United States. The programs funded by the Foundation will benefit people living with PD in 41 states. The Foundation invests in community programs that make an impact in local communities and help people live better with PD by providing support for health,
More news about: Parkinson's Foundation
Jul 28, 2026, 08:00 ET ZeroEyes, Advantech, Camden Police Department Partner to Bring AI Gun Detection Technology to Caesar Rodney School District
is remarkable, and I'm proud that they trust ZeroEyes to help keep schools safe.""We are excited to highlight the collaboration between Camden PD and Caesar Rodney SD in delivering a solution that strengthens a layered approach to student safety," said Ryne Johnson, Account Manager, Advantech.
More news about: ZeroEyes
Jul 28, 2026, 07:00 ET Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
formulation represents a differentiated strategy in a therapeutic area where disease-modifying treatment options remain limited, positioning Aramchol's PD program as an ideal out-licensing candidate.RAMAT-GAN, Israel, July 28,
More news about: Galmed Pharmaceuticals Ltd.